Featured News See All November 18, 2024 REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA November 14, 2024 REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202 November 6, 2024 REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates Year All202420232022202120202019201820172016201520142013201220112009 Sep 23, 2024 REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference Sep 17, 2024 REGENXBIO Appoints Mitchell Chan as Chief Financial Officer Sep 03, 2024 REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect Aug 29, 2024 REGENXBIO to Participate in Upcoming Investor Conferences Aug 27, 2024 REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium Aug 08, 2024 REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference Aug 01, 2024 REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
Sep 03, 2024 REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
Aug 27, 2024 REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
Aug 08, 2024 REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Aug 01, 2024 REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
